新型放射性杂合PET示踪剂用于SST2靶向神经内分泌肿瘤显像
本研究设计以DOTA为桥接单元的新型放射性杂合SST2示踪剂,可分别用18F或68Ga标记。七种DOTA-TATE衍生物中,引入亲水性三联肽的rhTATE2.1-2.5改善了亲和力与亲水性;[18F][natGa]rhTATE2.2肿瘤摄取最高,而[18F][natGa]rhTATE2.5背景清除更优、肿瘤/器官比值更好。
要点
- DOTA桥接的放射性杂合SST2示踪剂可用18F或68Ga标记。
- 亲水性三联肽修饰改善亲和力(IC50 2.6–3.7 nM)与亲水性。
- [18F][natGa]rhTATE2.5背景清除与肿瘤摄取可与[18F]SiTATE相比。
核心结论
- 研究验证了以双功能化DOTA为桥接单元的SST2靶向放射性杂合概念。
- N端亲水性三联肽修饰可改善药代动力学性质。
- [18F][natGa]rhTATE2.5在背景清除和肿瘤蓄积方面与[18F]SiTATE相当,并具放射性杂合成像的额外优势。
研究设计与样本
- 合成七种DOTA-TATE衍生物(rhTATE1/2及rhTATE2.1-2.5),并与[18F]SiTATE比较。
- 用hSST2-CHO细胞和[125I]TOC进行竞争结合实验测定IC50。
- 用AR42J细胞研究内化,用AR42J异种移植CD1 nu/nu小鼠进行生物分布与PET/CT研究。
- 通过共注射奥曲肽的阻断实验确认SST2特异性。
主要发现
- 第一代化合物亲和力良好([natGa]rhTATE1 IC50 5.6 ± 1.4 nM,[natGa]rhTATE2 IC50 5.7 ± 0.2 nM)但脂溶性高(LogDpH=7.4分别为-1.03和-1.19)。
- 引入亲水修饰后亲和力改善(IC50 2.6至3.7 nM),亲水性提高(LogDpH=7.4 -2.30至-2.12)。
- 化合物内化效率为[125I]TOC的357%至841%,人血清白蛋白亲和力为84.8%至98.8%。
- [18F][natGa]rhTATE2.2肿瘤蓄积最高(27.9 ± 4.8%iD/g),[18F][natGa]rhTATE2.5肿瘤摄取较低(18.6 ± 6.2%iD/g)但背景蓄积明显更低,肿瘤/器官比值改善。
临床怎么用
- 放射性杂合SST2示踪剂为神经内分泌肿瘤PET显像提供18F标记的替代选择。
- 亲水性三联肽修饰可用于优化示踪剂的药代动力学与靶本比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 68Ga- and 177Lu-labeled theranostic companion tracers have become a mainstay in the clinical management of SST2 overexpressing neuroendocrine tumors. Despite the excellent radionuclide characteristics of [18F]fluorine for PET imaging, 18F-labeled SST2-targeted tracers remain underrepresented. Novel radiohybrid SST2-tracers with DOTA as a bridging unit were designed, allowing radiolabeling with either 18F or 68Ga. METHODS: Seven DOTA-TATE derivatives (rhTATE1/2: N-SiFAlin-N, N-Me2-Gly-D-Dap/Lys(trans-DOTA-TATE)-OH and (rhTATE2.1-2.5: H-AA1-AA2-AA3-D-Dap(N-SiFAlin-N, N-Me2-Gly)-D-Lys(trans-DOTA-TATE)-OH) with different linkers and hydrophilic modifiers (AA1-AA3) were synthesized and compared to [18F]SiTATE. Competitive binding studies (IC50) were performed using hSST2-CHO cells and [125I]TOC. Internalization was investigated using AR42J cells. Biodistribution and PET/CT studies were performed using AR42J xenograft bearing CD1 nu/nu mice. SST2 specificity was confirmed in a blocking study (+/- co-injection of octreotide). RESULTS: While the first-generation compounds showed good affinity (IC50: [natGa]rhTATE1: 5.6 ± 1.4 nM, [natGa]rhTATE2: 5.7 ± 0.2 nM) but high lipophilicity (LogDpH=7.4 = -1.03 and - 1.19), the inclusion of hydrophilic modifiers ([natGa]rhTATE2.1-[natGa]rhTATE2.5) improved affinity (IC50: 2.6 to 3.7 nM) and hydrophilicity (LogDpH=7.4 = -2.30 to -2.12). The compounds demonstrated efficient internalization (357% to 841% compared to [125I]TOC), and variable human serum albumin affinity (84.8% to 98.8%). [18F][natGa]rhTATE2.2 showed the highest tumor accumulation (27.9 ± 4.8%iD/g), while [18F][natGa]rhTATE2.5 showed lower tumor uptake (18.6 ± 6.2%iD/g), but substantially lower background accumulation, providing improved tumor-to-organ ratios. CONCLUSION: This study demonstrates a SST2-targeted radiohybrid concept using bifunctionalized DOTA as a bridging unit. N-terminal modifications with hydrophilic tripeptides improved the pharmacokinetic properties. [18F][natGa]rhTATE2.5 (D-Glu-D-Glu-D-Glu) compares particularly well to [18F]SiTATE regarding background clearance and tumor accumulation, with the additional advantage of radiohybrid radiolabeling.
引用
- Wendlinger L, Parzinger M, Litvinenko A, et al. Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2025. PMID: 41128866. doi:10.1007/s00259-025-07638-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。